Thymosin Alpha-1 dosage for a large / giant breed
over 77 lb (35 kg)
The short answer
For a dog weighing over 77 lb (35 kg), the dose of Thymosin Alpha-1 reported in the literature is 3,500-8,000 mcg per dose, given 2-3x weekly, over 4-12 weeks or ongoing. It is studied in this weight class primarily for immune support, chronic infection, oncology adjunct. These figures are reported as published and are not recommendations — the dose for an individual dog must be set by a veterinarian who has examined the animal.
Worked examples at specific weights
Calculated from the reported range of 50–100 mcg per kg of body weight.
| Body weight | Calculated dose range | Frequency |
|---|---|---|
| 40 kg (88 lb) | 2000–4000 mcg | 2-3x weekly |
| 50 kg (110 lb) | 2500–5000 mcg | 2-3x weekly |
| 60 kg (132 lb) | 3000–6000 mcg | 2-3x weekly |
For an exact figure at your dog's weight, use the dose calculator.
Typical breeds in this weight class
German Shepherd, Labrador Retriever, Rottweiler, Great Dane, Mastiff and similarly sized dogs generally fall within over 77 lb (35 kg). Weigh your dog rather than estimating — dosing is calculated per kilogram and an estimate that is out by a few kilos changes the figure materially, particularly at the smaller end.
Common questions
How much Thymosin Alpha-1 for a large / giant breed?+
For a dog in the over 77 lb (35 kg) range, the reported dose is 3,500-8,000 mcg per dose, given 2-3x weekly, typically for 4-12 weeks or ongoing. At a representative weight of 45 kg (about 99 lb), that works out to roughly 2250–4500 mcg per dose. These figures are reported from the source literature and are not recommendations.
How often should a large / giant breed be given Thymosin Alpha-1?+
2-3x weekly is the reported frequency, over a course of 4-12 weeks or ongoing. See the cycling guide for how breaks are structured.
Is Thymosin Alpha-1 safe for a large / giant breed?+
Thymosin alpha-1 has the most established safety profile of anything covered here, having been approved for human use in more than 35 countries for decades with no cumulative toxicity reported. It is also notable as an exception to the cancer contraindication that applies to most growth-promoting peptides — published data suggests it may support immune surveillance without appearing to promote tumour growth. The honest limitation is that essentially all of that evidence is human; no canine clinical trials exist.
References
- 1.King R, Tuthill C Immune modulation with thymosin alpha 1 treatment. Vitamins and Hormones, 2016. PMID 27450734
- 2.Dominari A, et al. Thymosin alpha 1: a comprehensive review of the literature. World Journal of Virology, 2020. PMID 33362999
- 3.Bellet MM, et al. Thymosin Alpha 1 in Cancer Therapy: Where Do We Stand?. Frontiers in Oncology, 2019. View source
- 4.Guo Y, et al. Thymosin alpha 1 suppresses proliferation of breast cancer cells via PTEN/PI3K/Akt/mTOR. Apoptosis, 2015. View source
- 5.Wang F, et al. Thymosin alpha-1-Fc modulates the immune system with prolonged half-life. Scientific Reports, 2018. PMID 30120313
Other weight classes: Thymosin Alpha-1 for a small / toy breed, Thymosin Alpha-1 for a medium breed.
Educational information — not veterinary medical advice
Everything on this page is compiled from published peer-reviewed literature for educational and research purposes. It does not establish a veterinarian-client-patient relationship (VCPR) and is not a substitute for veterinary examination and diagnosis. Most compounds described here are investigational or used off-label and are not FDA-approved for these purposes in dogs. Extralabel drug use in animals requires a valid VCPR and the direct supervision of a licensed veterinarian under AMDUCA (21 U.S.C. §360b). Dosing figures are reported as they appear in the source literature and are not recommendations.